Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA systemGHB, GBL, phenibut +1 moreGHB, GBL, phenibut, other GABA-B active agents show less
Baclofen
β-(4-chlorophenyl)-γ-aminobutyric acid
Baclofen is a synthetic depressant of the GABA structural analog class.[1] It is a modified form of GABA — the brain's main calming signal — built to cross the blood-brain barrier. It activates GABA receptors, quieting nerve activity and producing muscle relaxation and sedation.[2]
Baclofen (β-(4-chlorophenyl)-GABA) is a synthetic depressant of the GABA structural analog class. It is a lipophilic derivative of GABA, designed to cross the blood-brain barrier. Baclofen is a selective GABA-B receptor agonist,[1] producing its effects by suppressing neuronal excitability through calcium channel inhibition and potassium channel activation.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA systemGHB, GBL, phenibut +1 moreGHB, GBL, phenibut, other GABA-B active agents show less
Synthesized in 1962 as an experimental anti-seizure drug, it failed that purpose but revealed strong muscle-relaxing effects.[1] In 2005, Olivier Ameisen published a self-case report describing complete suppression of alcohol dependence at doses up to 270 mg/day.[3] France formally approved baclofen for alcohol use disorder in 2020, the first country to do so.[4]
Subjective effects include muscle relaxation, sedation, reduced anxiety, and cognitive slowing.[5] The experience is defined by a flat, clean calm — tension dissolves without the warmth or euphoria of alcohol or benzodiazepines. Drowsiness, cognitive fatigue, and impaired coordination are common unsought effects, intensifying at higher doses.
Baclofen produces physical dependence with regular use,[6] and overdose can cause respiratory failure and fixed pupils that mimic brain death.[7][8] Kidney function is the key variable — the drug exits unchanged through the kidneys,[9] so impaired kidneys allow dangerous accumulation. Fifty years of clinical use provide substantial safety data, though a human lethal dose remains unestablished.
History[edit]
Discovery
Baclofen was synthesized in 1962 by Heinrich Keberle at Ciba-Geigy, following research interest in making GABA-like molecules that could cross into the brain.[1][10] The design attached a chlorinated ring to GABA, making the molecule fat-soluble enough to pass the blood-brain barrier. It failed as an anti-seizure drug but proved effective at reducing muscle spasticity, so development shifted entirely.[10]
Clinical Adoption
The FDA approved baclofen in 1977 under the brand name Lioresal for spasticity in multiple sclerosis and spinal cord injury[1] — three years before its molecular target was formally identified. By the early 1980s, intrathecal delivery was developed: implanted pumps that deliver the drug directly into spinal fluid for patients who don't respond to oral treatment.[11]
Baclofen and Alcohol Use Disorder
In 2005, Olivier Ameisen published a self-case report describing complete suppression of alcohol dependence at doses up to 270 mg/day.[3] The account sparked a public movement and a 2014 French ruling permitting doses up to 300 mg/day.[12] France formally approved baclofen for alcohol use disorder as Baclocur in 2020, capping the approved dose at 80 mg/day.[4]
Chemistry[edit]
Structural Class
Baclofen is a GABA structural analog — built on the same amino acid backbone as GABA, the brain's primary calming chemical, with a chlorine-bearing ring attached to one end.[1] That ring makes the molecule fat-soluble enough to cross the blood-brain barrier, which natural GABA cannot do.[13][1]
| Molecular formula | C₁₀H₁₂ClNO₂ |
| Molecular weight | 213.66 g/mol |
Stereochemistry
The commercial drug is a racemate — an equal mix of two mirror-image molecules. The R-enantiomer (arbaclofen) carries essentially all the pharmacological activity; the S-form is inactive at GABA-B receptors.[1][14] Arbaclofen placarbil, a prodrug of the R-form designed for better absorption, has been studied in clinical trials for autism spectrum disorder and fragile X syndrome.[1]
Pharmacology[edit]
Mechanism of Action
Baclofen is the only FDA-approved selective GABA-B receptor agonist.[1] At nerve terminals in the spinal cord, it reduces the release of excitatory chemicals — particularly glutamate — quieting the overactivated pathways responsible for spasticity.[15][16]
In the brain's reward circuits, baclofen suppresses dopamine release.[17] This blunts the motivational drive toward alcohol and other substances, explaining both its anti-craving effect and its low potential for producing euphoria or addiction.
Pharmacokinetics
Baclofen is well absorbed orally, peaking in the bloodstream around 2 hours[18][13] with a half-life of about 3.5 hours.[13] The liver barely processes it — 65–70% exits the body unchanged through the kidneys.[18][9] Impaired kidney function causes accumulation and toxicity at standard doses.[9][19]
Neuroscience[edit]
Where It Acts
Baclofen's anti-craving effect originates in midbrain dopamine neurons — GABA-B activation there suppresses dopamine release into the brain's reward center.[17] Neuroimaging confirms this: baclofen reduces brain reactivity to alcohol-related cues in craving and emotion regions.[20][21] In the spinal cord, similar receptor activation at sensory terminals reduces the overactivated signals that cause spasticity.[15]
Why It Matters
Baclofen targets the motivational pull toward alcohol — the craving — without making drinking feel aversive. Patients stop reaching for alcohol without experiencing its absence as deprivation. It also lowers stress hormone (cortisol) levels in alcohol-dependent patients,[22] providing anxiety relief that may reduce stress-driven relapse.
The dose-response relationship for anti-craving efficacy versus adverse effects remains incompletely mapped. French data support doses above 80 mg/day,[12] but formal approval caps there.[4] Specific binding affinity values at GABA-B receptors have never been published — an unusual gap for a drug with over fifty years of clinical use.
Subjective Effects[edit]
Baclofen's experience is defined by muscular quieting rather than mental alteration. Tension releases and anxiety lifts, while thinking stays relatively clear at low doses. As doses increase, sedation deepens and cognition slows, moving toward a heavier state of psychomotor sluggishness and memory gaps.
Compared to GHB, baclofen produces far less euphoria and social warmth, consistent with its low abuse liability.[5] Relative to benzodiazepines, its cognitive effects are less amnestic at comparable sedation levels — though this distinction narrows at higher doses. It sits closer to a quiet off-switch than to the chemical ease of alcohol.
Synthesized in 1962 by Heinrich Keberle at Ciba-Geigy as an experimental antiepileptic, baclofen failed its original indication but revealed potent muscle-relaxing properties during early trials.[1] A 2005 self-case report by Olivier Ameisen describing high-dose baclofen for alcohol dependence reshaped the drug's trajectory.[3] France became the first country to approve baclofen specifically for alcohol use disorder in 2020, though the approved dose remains capped below the levels used in practice.[4]
Subjective effects include muscle relaxation, sedation, anxiolysis, and cognitive slowing. The experience is one of quiet muscular softening — tension dissolves without the diffuse warmth or affective glow of benzodiazepines or alcohol, replaced by a flat, clean calm that lacks euphoriant character.[5] Drowsiness, cognitive fatigue, and psychomotor impairment are common unsought effects.
Baclofen produces physical dependence with regular use,[6] and acute overdose can mimic brain death — fixed dilated pupils, respiratory failure, and seizures.[7][8] The primary risk is shaped by renal function: 65–70% of the drug is excreted unchanged by the kidneys, so impaired clearance converts standard doses into toxic exposures.[9] Over fifty years of clinical use provide extensive safety data, though specific binding affinities and a human lethal dose remain unestablished.
History[edit]
Discovery
Baclofen was synthesized in 1962 by Heinrich Keberle at Ciba-Geigy in Basel, following a conference that catalyzed interest in blood-brain-barrier-penetrant GABA analogs.[1][10] The design was direct: attach a para-chlorophenyl group to GABA to increase lipophilicity and permit central nervous system entry. Intended as an antiepileptic, baclofen failed that purpose — but patients in early trials showed marked reductions in spasticity, redirecting development entirely.[10]
Clinical Adoption
The U.S. FDA approved baclofen in 1977 under the brand name Lioresal for spasticity in multiple sclerosis and spinal cord injuries — three years before Norman Bowery formally characterized the GABA-B, making baclofen an approved drug before its molecular target was understood.[1] In the early 1980s, intrathecal delivery was developed for severe, treatment-resistant spasticity, delivering the drug directly to cerebrospinal fluid at microgram-level doses.[11]
Baclofen and Alcohol Use Disorder
In 2005, French-American cardiologist Olivier Ameisen published a self-case report describing complete suppression of alcohol dependence at doses up to 270 mg/day — far exceeding the standard 80 mg/day spasticity ceiling.[3] His account of achieving "indifference" to alcohol triggered a social movement in France and unprecedented regulatory action: a 2014 Temporary Recommendation for Use permitting doses up to 300 mg/day,[12] followed in 2020 by formal marketing authorization for Baclocur — making France the first country to approve baclofen specifically for alcohol use disorder, with a dose cap of 80 mg/day.[4]
Chemistry[edit]
Structural Class
Baclofen is a GABA structural analog — a derivative of γ-aminobutyric acid bearing a para-chlorophenyl group at the β-carbon.[1] Despite superficial resemblance to phenethylamines, baclofen's four-carbon amino acid backbone is structurally distinct from the two-carbon phenethylamine scaffold. The IUPAC name is 4-amino-3-(4-chlorophenyl)butanoic acid.
The chlorine at the para position of the phenyl ring enhances lipophilicity relative to unsubstituted GABA, enabling blood-brain barrier penetration — the original design rationale.[13][1]
| Molecular formula | C₁₀H₁₂ClNO₂ |
| Molecular weight | 213.66 g/mol |
Stereochemistry
Baclofen has one chirality center at C-3, producing two enantiomers. The commercial drug is a racemate. The R-enantiomer (arbaclofen) carries essentially all GABA-B activity; the S-enantiomer is pharmacologically inactive at this target.[1][14] The S-enantiomer undergoes liver metabolism to an oxidative metabolite, whereas the R-enantiomer is minimally metabolized.[14]
Arbaclofen placarbil (STX209), a prodrug of R-baclofen designed for improved intestinal absorption, has been investigated in clinical trials for autism spectrum disorder and fragile X syndrome.[1]
Pharmacology[edit]
Mechanism of Action
Baclofen is the only FDA-approved selective GABA-B receptor agonist.[1] The GABA-B is a G protein-coupled receptor that operates as an obligatory two-part complex — a GB1 subunit that binds the drug and a GB2 subunit that activates inhibitory G proteins.[2][15] Baclofen binds the GB1 subunit, triggering a shape change that allows GB2 to engage its signaling cascade.[2]
At nerve terminals, this activation suppresses calcium channels (N-type and P/Q-type), reducing neurotransmitter release — particularly glutamate and substance P in the spinal cord, which produces the antispastic effect.[16][17] On the receiving side of the synapse, the receptor opens potassium channels that quiet the neuron, contributing to sedation and anxiolysis.[18]
Baclofen also suppresses dopamine release in reward circuits via GABA-B receptors on dopaminergic terminals.[19] This dampening of reward signaling underlies its anti-craving effects in alcohol use disorder and its low potential for producing euphoria.
Beyond the central nervous system, baclofen inhibits the cough reflex[20][21] and reduces gastroesophageal reflux by acting on vagal GABA-B receptors that control lower esophageal sphincter relaxation.[22][23]
Pharmacokinetics
Baclofen is well absorbed orally, with bioavailability of 70–85%.[13] Peak plasma levels occur at approximately 2 hours,[24][13] with a plasma half-life of roughly 3.5 hours.[13] Protein binding is low at 30–35%.[24]
Absorption occurs through a specialized transport system in the mid-small intestine that saturates at higher doses.[25] Colonic absorption is negligible, limiting the viability of sustained-release formulations.[25]
The drug undergoes minimal liver metabolism.[9] Instead, 65–70% is excreted unchanged by the kidneys,[24][9] making kidney function the primary determinant of drug clearance. In patients with renal impairment, the drug accumulates and can produce toxicity at standard doses.[9][26] Food does not significantly affect absorption.[27]
At doses substantially exceeding 80 mg/day, peak time and half-life may be prolonged, likely reflecting saturation of clearance pathways.[28]
Neuroscience[edit]
Where It Acts
Baclofen's anti-craving effects trace to GABA-B receptors on dopaminergic neurons projecting from the ventral tegmental area to the nucleus accumbens, where it suppresses reward-related dopamine release.[19] Neuroimaging in alcohol-dependent individuals shows that baclofen reduces alcohol cue-related activation across the orbitofrontal cortex, amygdala, and insula[29][30] — the insula being an interoceptive hub whose suppression may explain the reported "indifference" to alcohol.
At the spinal level, GABA-B activation on sensory nerve terminals reduces excitatory signaling onto motor neurons, producing the antispastic effect.[16]
Why It Matters
Baclofen's clinical profile maps onto the incentive salience framework: by suppressing mesolimbic dopamine, it reduces wanting (the motivational pull toward a substance) without necessarily altering liking (hedonic pleasure). The clinical result is indifference rather than aversive conditioning — patients stop wanting alcohol without experiencing its absence as deprivation.
Baclofen also moderates the stress-hormone axis, reducing cortisol responses in alcohol-dependent patients.[31] This provides a basis for anxiolysis independent of direct neuronal inhibition and may contribute to reduced stress-driven relapse.
The dose-response relationship for anti-craving efficacy versus adverse effects remains incompletely mapped. French data support doses above 80 mg/day,[12] but formal approval caps at that level.[4] Specific binding affinity values at human GABA-B receptors have never been published — an unusual gap for a drug with over fifty years of clinical use.
Subjective Effects[edit]
The baclofen experience is defined by muscular quieting rather than mental alteration. At low therapeutic doses, tension softens and anxiety recedes without clouded thinking or emotional suppression. As dose increases, sedation deepens and cognition slows — above 80 mg/day, the profile shifts toward a heavier state marked by psychomotor impairment and amnesia. Individual response varies substantially with kidney function, which governs effective drug exposure, and with baseline GABAergic tone.
Compared to GHB, baclofen produces markedly less euphoria and social disinhibition, consistent with its low abuse liability.[5] Relative to benzodiazepines, its cognitive effects are less amnestic at equivalent sedation levels, though this distinction narrows at higher doses.
Effect Grid
At 20–50 mg oral, baclofen produces pronounced muscle relaxation, moderate sedation, and clear anxiolysis. Cognitive fatigue becomes apparent — thought deceleration is noticeable, and concentration requires more effort than usual. The mental state is quiet rather than intoxicated; there is no euphoric warmth or affective enhancement.
Physically, dizziness is common, nausea may occur, and motor control impairment becomes a practical concern. Pain suppression is noticeable. Some individuals report increased urination or mild gastrointestinal effects.
This range covers standard spasticity dosing and the lower end of alcohol use disorder treatment. Driving and operating machinery should be avoided. Doses are per-administration, not daily totals.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
External hallucinations
Physical fatigue · Bodily heaviness · Pain suppression · Nausea · Body high · Constipation · Dry mouth · Headache · Brain zaps · Breathing alteration · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vomiting · Temperature dysregulation · Bodily dissociation
Nausea · Body high · Constipation · Dry mouth · Headache · Brain zaps · Breathing alteration · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vomiting · Bodily dissociation
Confusion · Language suppression · Memory suppression · Thought disorganization · Amnesia · Delirium
Thought disorganization · Delirium
Timeline
Initial awareness of muscular softening begins. A subtle calming may be perceptible, though effects are sub-threshold for most individuals.
Muscle relaxation deepens progressively. Mild sedation and emerging anxiolysis become noticeable. Slight dizziness or nausea may appear.
Maximum muscle relaxation, peak anxiolysis, and most pronounced sedation. Cognitive slowing and thought deceleration are at their strongest. Pain suppression is maximal.
Sedation and cognitive effects gradually diminish. Muscle relaxation persists longer than mental effects. Motor coordination begins to return.
Residual muscular relaxation, mild fatigue, and possible lingering cognitive slowing.
⚠ Avoid driving or operating heavy machinery for up to 12 hours, as residual sedation and motor impairment may persist.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Low
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- GHB · GBL · phenibut
Toxicity
Acute Toxicity
Acute baclofen overdose is a medical emergency. High doses cause profound loss of consciousness, respiratory failure, seizures, and fixed dilated pupils that can mimic brain death.[8][7] Heart rhythm disturbances and dangerously low body temperature also occur.[23]
Full neurological recovery is possible even after presentations that look like brain death. One teenager with no detectable consciousness and fixed pupils recovered completely within two days of supportive care.[8] Recognizing this potential for recovery is critical — premature withdrawal of care must be avoided.
No specific antidote exists. Flumazenil — used to reverse benzodiazepines — does not work for baclofen. Treatment is entirely supportive: airway protection, breathing support, blood pressure management, and seizure control. Dialysis may help patients with kidney impairment but offers little benefit when kidneys function normally.[24][25]
No human lethal dose has been established. The toxic threshold varies widely between individuals. safety citation needed
Toxicity in Kidney Impairment
Impaired kidneys cannot clear baclofen normally, causing the drug to accumulate.[9][19] This has produced brain dysfunction and coma in patients with kidney disease at doses safe for healthy adults. A single standard dose triggered serious brain toxicity in a dialysis patient.[26]
Chronic Toxicity
No specific long-term organ damage has been identified. Baclofen is safe for the liver and has been used in patients with cirrhosis without toxic effects[27] — a significant advantage over most sedative drugs.
Brain Toxicity
Baclofen can produce a metabolic brain disturbance with abnormal electrical patterns on brainwave testing. Combining it with benzodiazepines worsens this beyond simple additive sedation.[28]
Respiratory Effects
Breathing suppression is a risk even at standard doses in susceptible individuals. Central sleep apnea has been documented at doses as low as 10 mg.[29]
Pregnancy
Baclofen is classified FDA Pregnancy Category C. A study of 134 women exposed during early pregnancy found increased risk of major birth defects.[30] Newborns exposed before birth have experienced withdrawal seizures and vital sign instability.[31][32]
Psychological Risks
At therapeutic doses, cognitive fatigue, confusion, and drowsiness are the main psychological effects. Higher doses bring deeper cognitive blunting — amnesia and impaired judgment become more pronounced. Delirium occurs primarily during acute overdose or abrupt withdrawal, and withdrawal-related delirium can be severe.[6]
Depression and suicidal thoughts have been reported in post-marketing surveillance, though separating baclofen's contribution from baseline psychiatric risk in alcohol-dependent populations is difficult. Baclofen does not produce psychedelic-type psychological risks — its profile is that of a sedative, with effects scaling with dose.
Tolerance & Dependence
Abrupt discontinuation of baclofen produces a potentially life-threatening withdrawal syndrome. Baclofen should always be tapered gradually.
Physical dependence develops with regular use.[6] Tolerance to therapeutic effects can appear within days. The withdrawal syndrome includes fever, rapid heart rate, severe agitation, seizures, and delirium — onset can begin within 24 hours of the last dose.[33] This syndrome occurs with both oral and intrathecal forms.[6]
Baclofen rarely produces euphoria or drug craving, giving it lower psychological dependence potential than benzodiazepines.[5] Newborn withdrawal has been documented in infants exposed before birth.[32][31] Cross-tolerance with other GABA-B-active substances is expected based on shared receptor pharmacology.
Drug Interactions
Baclofen's most dangerous interactions are with other central nervous system depressants. Because the drug is barely processed by the liver, enzyme-based interactions are not a significant concern.[9]
- GHB/GBL: Near-additive GABA-B activation produces synergistic sedation and breathing suppression. Classified as a lethal interaction.[34]
- Alcohol: Overlapping GABA pathways combine to suppress breathing at potentially lethal levels.[35] Baclofen is used to reduce alcohol craving, but drinking while taking it compounds sedation dangerously.
- Opioids: Additive breathing suppression through independent mechanisms. Life-threatening episodes have been documented with intrathecal baclofen combined with opioid painkillers.[36]
- Benzodiazepines: These specifically worsen baclofen-related brain toxicity, producing EEG-confirmed metabolic disturbance beyond simple sedation.[28]
- Methaqualone: Additive-to-synergistic sedation via GABA-A and glycine receptor modulation. Classified as a lethal interaction based on pharmacological evidence.
Contraindications
12 knownAbsolute
- Severe kidney impairment (eGFR <30 mL/min/1.73 m²): Rapid drug accumulation produces brain dysfunction and coma at standard doses.[9][19][26]
Relative
- Moderate kidney impairment: Requires dose reduction and close monitoring.[18]
- Pregnancy: Increased birth defect risk;[30] neonatal withdrawal if used until birth.[31]
- Seizure disorder: Baclofen may lower seizure threshold; seizures occur in both overdose and withdrawal.
- Sleep-disordered breathing: Central sleep apnea documented at 10 mg.[29]
- Concurrent CNS depressant use: Especially opioids,[36] benzodiazepines,[28] GHB/GBL, and alcohol.
- Psychiatric instability: Depression and suicidal ideation reported in post-marketing surveillance.
Harm Reduction[edit]
Forms & Identification
Baclofen circulates almost exclusively as pharmaceutical tablets in 5 mg, 10 mg, 20 mg, and 25 mg strengths. Adulteration is not the primary concern — the main risk is taking the wrong tablet strength, particularly when tablets are obtained without original packaging. Pill identification tools matching imprint codes to manufacturer databases are the most reliable verification method.
Guidelines
- Confirm kidney function before initiating regular use — impaired kidneys dramatically increase toxicity risk at standard doses.
- Start at the lowest available dose (5 mg) and increase gradually over days.
- Never skip doses or stop abruptly after regular use. Taper slowly under medical guidance.
- Avoid driving or operating machinery until individual sedation response is established.
- Keep doses separated by at least 4 hours to prevent accumulation between peaks.
- Do not exceed prescribed doses. High-dose protocols for alcohol use disorder require medical supervision.
- Store tablets in original packaging with clear labeling to prevent dose confusion.
Set & Setting
Dose is the primary variable with baclofen — environment plays a minimal role. Kidney function determines actual drug exposure, and concurrent sedative use compounds risk significantly. Initial doses should be taken in a safe setting where drowsiness and impaired coordination cannot create hazards, particularly avoiding driving or operating machinery.
Aftercare & integration. Baclofen does not produce intense psychological experiences requiring formal integration. Post-use recovery centers on physical recovery — wait for sedation to clear fully before resuming demanding cognitive or physical tasks. For alcohol craving management, anti-craving effects fluctuate through the day due to the short half-life; craving returning between doses is pharmacokinetic, not treatment failure. Stay hydrated and monitor for unusual confusion or drowsiness, which may indicate drug accumulation.
Recovery & Support
Physical dependence on baclofen requires medically supervised tapering to discontinue safely. Abrupt cessation risks life-threatening withdrawal including seizures and delirium. Tapering typically reduces the dose by 5–10 mg every few days, though individual timelines vary with dose magnitude and duration of use.
For individuals using baclofen to manage alcohol dependence, discontinuation should be coordinated with broader addiction treatment. Support resources include addiction medicine specialists, SMART Recovery, and mutual aid groups. Withdrawal management may require inpatient monitoring, particularly at doses above 80 mg/day.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Unresponsive or cannot be woken
- Breathing is very slow, shallow, or has stopped
- Seizures
- Fixed, dilated pupils (do not assume brain death — recovery is possible)
- Blue lips or fingertips
- Body temperature dropping noticeably
Immediate steps:
- 1. Call emergency services immediately.
- 2. Place the person in the recovery position if breathing but unconscious.
- 3. Monitor breathing continuously. Begin rescue breathing if it stops.
- 4. Do not induce vomiting.
- 5. Do not administer flumazenil — it does not work for baclofen.
- 6. Keep the person warm — hypothermia is common in overdose.
What to tell the dispatcher:
Substance name (baclofen), estimated amount taken, time of ingestion, and current symptoms. Include any known kidney problems. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents:
No specific antidote exists. Treatment is entirely supportive. Dialysis is generally ineffective in patients with normal kidney function.
Legal Status[edit]
Baclofen is a prescription-only medication in all major jurisdictions and is not classified as a controlled substance anywhere.[5] France is the only country to have approved it specifically for alcohol use disorder.[12][4]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Prescription-only; not DEA scheduled | FDA approved 1977 for spasticity (Lioresal). No controlled substance designation. |
| United Kingdom | Prescription-only medicine (POM) | Not controlled under the Misuse of Drugs Act 1971. |
| European Union | Prescription-only (all member states) | France: Baclocur approved for AUD (2020), max 80 mg/day. Other member states: spasticity indication only. |
| France | Prescription-only; AUD indication approved | TRU 2014–2017 (up to 300 mg/day); formal Baclocur authorization June 2020 (80 mg/day cap).[4] |
| Canada | Prescription-only | No controlled substance scheduling. |
| Australia | Prescription-only (TGA approved) | No controlled substance scheduling. |
Legal status varies by jurisdiction and changes over time. This information is not legal advice — verify current status through official sources before relying on it.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Low
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- GHB · GBL · phenibut
Toxicity
Acute Toxicity
Acute baclofen overdose is a medical emergency. Toxicity has been documented at single ingestions exceeding 200 mg.[7] The clinical picture includes profound loss of consciousness, respiratory failure, dangerously slow heart rate, low blood pressure, low body temperature, seizures, and fixed dilated pupils that can mimic brain death.[8] Heart rhythm disturbances[32] and rare lung complications including collapsed lung tissue[7] have also been reported.
Full neurological recovery is possible even after presentations resembling brain death. A 15-year-old who presented with no detectable consciousness and fixed pupils recovered completely within two days with supportive care.[8] This capacity for recovery must be recognized to prevent premature withdrawal of care.
No specific antidote exists. Flumazenil is ineffective — baclofen does not act at benzodiazepine receptors. Management is entirely supportive: airway protection, mechanical ventilation, blood pressure support, and seizure treatment. Dialysis may help in patients with kidney impairment but offers little benefit when kidney function is normal.[33][34]
No human lethal dose has been established. The toxic threshold varies widely between individuals. safety citation needed
Toxicity in Kidney Impairment
Patients with impaired kidney function face dramatically elevated risk at standard doses. Because baclofen is primarily cleared by the kidneys, reduced function leads to drug accumulation, producing confusion, brain dysfunction, and coma.[9][26] A single standard dose has triggered serious brain dysfunction in a dialysis patient.[35]
Chronic Toxicity
No specific long-term organ damage has been identified. Baclofen is notably safe for the liver and has been used in patients with liver cirrhosis without toxic effects[36] — a significant advantage over most sedative drugs.
Brain Toxicity
Baclofen can produce a metabolic brain disturbance with characteristic electrical changes on EEG. Concurrent benzodiazepine use worsens this beyond simple additive sedation.[37]
Respiratory Effects
Central sleep apnea has been documented at doses as low as 10 mg, indicating respiratory risk even at standard doses in susceptible individuals.[38]
Pregnancy
Baclofen is classified FDA Pregnancy Category C. A study of 134 women exposed during early pregnancy found increased risk of major birth defects.[39] Newborn withdrawal syndrome — including seizures and instability of vital signs — has been documented in infants exposed before birth.[40][41]
Psychological Risks
At therapeutic doses, cognitive fatigue, confusion, and drowsiness are the primary psychological effects. At doses above 80 mg/day used in alcohol treatment, cognitive blunting intensifies — amnesia, thought deceleration, and decision impairment become more pronounced.
Delirium occurs primarily during acute overdose and abrupt withdrawal. Withdrawal-related delirium can be severe and prolonged.[6]
Depression and suicidal thoughts have been reported in post-marketing surveillance, though separating baclofen's contribution from the high baseline psychiatric burden in alcohol-dependent populations is difficult. Baclofen does not produce psychedelic-type psychological risks; its profile is that of a sedative — cognitive impairment and emotional suppression scaling with dose.
Tolerance & Dependence
Abrupt discontinuation of baclofen produces a potentially life-threatening withdrawal syndrome. Baclofen should always be tapered gradually.
Physical dependence develops with regular use.[6] Tolerance to therapeutic effects appears within days of continuous use. Baclofen rarely produces euphoria or drug craving, giving it lower psychological dependence potential than benzodiazepines.[5]
The withdrawal syndrome includes fever, rapid heart rate, severe agitation, seizures, delirium, and rebound effect spasticity in patients treated for that condition. Onset can be rapid — agitation, weakness, fever, and fast heart rate within 24 hours of the last dose.[42] This syndrome occurs with both oral and intrathecal baclofen.[6]
Newborn withdrawal has been documented in infants exposed before birth.[41][40] Cross-tolerance with other GABA-B-active substances is expected based on shared receptor pharmacology.
Drug Interactions
Baclofen's interaction profile is dominated by additive effects with other central nervous system depressants. Because the drug undergoes minimal liver metabolism, interactions based on liver enzyme competition are not a significant concern.[9]
- GHB/GBL: Near-additive GABA-B receptor activation producing synergistic sedation and respiratory depression. Classified as a lethal interaction.[43]
- Alcohol: Synergistic sedation and respiratory depression through overlapping GABA pathways.[44] Baclofen is used clinically to reduce alcohol craving, but concurrent consumption potentiates sedation to a potentially lethal degree.
- Opioids: Additive respiratory depression through independent mechanisms. Life-threatening episodes have been documented with intrathecal baclofen combined with opioid painkillers.[45]
- Benzodiazepines: Beyond additive sedation, benzodiazepines specifically worsen baclofen-related brain toxicity, producing EEG-confirmed metabolic disturbance distinct from simple sedative summation.[37]
- Methaqualone: Additive-to-synergistic sedation via GABA-A and glycine receptor modulation. Classified as a lethal interaction based on pharmacological plausibility.
Contraindications
12 knownAbsolute
- Severe kidney impairment (eGFR <30 mL/min/1.73 m²): Baclofen accumulates rapidly, producing brain dysfunction and coma at standard doses.[9][26][35]
Relative
- Moderate kidney impairment: Requires dose reduction and close monitoring.[24]
- Pregnancy: Increased birth defect risk documented;[39] neonatal withdrawal if exposed until birth.[40]
- Seizure disorder: Seizures occur in both overdose and withdrawal; baclofen may lower seizure threshold.
- Sleep-disordered breathing: Central sleep apnea documented at 10 mg.[38]
- Concurrent CNS depressant use: Especially opioids,[45] benzodiazepines,[37] GHB/GBL, and alcohol.
- Psychiatric instability: Depression and suicidal ideation reported in post-marketing surveillance.
Harm Reduction[edit]
Forms & Identification
Baclofen circulates almost exclusively as pharmaceutical tablets in 5 mg, 10 mg, 20 mg, and 25 mg strengths. Because it is a prescription medication produced by multiple manufacturers worldwide, the primary identification concern is not adulteration but correct identification of tablet strength — particularly when tablets are obtained without original packaging. Pill identification tools matching imprint codes to manufacturer databases are the most reliable verification method.
Guidelines
- Confirm kidney function before initiating regular use — impaired kidneys dramatically increase toxicity risk at standard doses.
- Start at the lowest available dose (5 mg) and increase gradually over days.
- Never skip doses or stop abruptly after regular use. Taper slowly under medical guidance.
- Avoid driving or operating machinery until individual sedation response is established.
- Keep doses separated by at least 4 hours to prevent accumulation between peaks.
- Do not exceed prescribed doses. High-dose protocols for alcohol use disorder require medical supervision.
- Store tablets in original packaging with clear labeling to prevent dose confusion.
Set & Setting
The primary experiential variable with baclofen is dose, not environment. Unlike psychedelics or empathogens, set and setting play a minimal role in shaping the experience. The relevant contextual factors are physical: kidney function determines effective exposure, and concurrent sedative use compounds risk. First-time users should take initial doses in a safe environment where drowsiness and impaired coordination will not create hazards — particularly avoiding driving or operating machinery.
Aftercare & integration. Baclofen does not produce intense psychological experiences requiring formal integration. Post-use considerations center on physical recovery: allow sedation to clear fully before resuming demanding cognitive or physical tasks. If using baclofen for alcohol craving management, be aware that the drug's short half-life means anti-craving effects fluctuate through the day — between-dose craving return is pharmacokinetic, not treatment failure. Maintain hydration and monitor for any unusual confusion or drowsiness that could indicate accumulation.
Recovery & Support
Physical dependence on baclofen develops with regular use and requires medically supervised tapering to discontinue safely. Abrupt cessation risks life-threatening withdrawal including seizures and delirium. Tapering schedules typically reduce the dose by 5–10 mg every few days, though individual timelines vary with dose magnitude and duration of use.
For individuals using baclofen to manage alcohol dependence, discontinuation should be coordinated with broader addiction treatment. Support resources include addiction medicine specialists, SMART Recovery, and mutual aid groups. Withdrawal management may require inpatient monitoring, particularly at doses above 80 mg/day.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Unresponsive or cannot be woken
- Breathing is very slow, shallow, or has stopped
- Seizures
- Fixed, dilated pupils (do not assume brain death — recovery is possible)
- Blue lips or fingertips
- Body temperature dropping noticeably
Immediate steps:
- 1. Call emergency services immediately.
- 2. Place the person in the recovery position if breathing but unconscious.
- 3. Monitor breathing continuously. Begin rescue breathing if it stops.
- 4. Do not induce vomiting.
- 5. Do not administer flumazenil — it does not work for baclofen.
- 6. Keep the person warm — hypothermia is common in overdose.
What to tell the dispatcher:
Substance name (baclofen), estimated amount taken, time of ingestion, and current symptoms. Note any kidney problems if known. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents:
No specific antidote exists. Treatment is entirely supportive. Dialysis is generally ineffective in patients with normal kidney function.
Legal Status[edit]
Baclofen is a prescription-only medication in all major jurisdictions. It is not classified as a controlled substance under any drug scheduling framework — reflecting its low abuse liability relative to benzodiazepines and other sedative agents.[5] Baclofen appears on the WHO Essential Medicines List for spasticity management.
France occupies a unique regulatory position as the first and only country to approve baclofen specifically for alcohol use disorder. The 2014 Temporary Recommendation for Use permitted doses up to 300 mg/day; the formal 2020 marketing authorization (Baclocur, Ethypharm) capped the approved AUD dose at 80 mg/day.[12][4]
No structural analog act applicability has been identified — baclofen is a named, approved pharmaceutical in all major jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Prescription-only; not DEA scheduled | FDA approved 1977 for spasticity (Lioresal). No controlled substance designation. |
| United Kingdom | Prescription-only medicine (POM) | Not controlled under the Misuse of Drugs Act 1971. |
| European Union | Prescription-only (all member states) | France: Baclocur approved for AUD (2020), max 80 mg/day. Other member states: spasticity indication only. |
| France | Prescription-only; AUD indication approved | TRU 2014–2017 (up to 300 mg/day); formal Baclocur authorization June 2020 (80 mg/day cap).[4] |
| Canada | Prescription-only | No controlled substance scheduling. |
| Australia | Prescription-only (TGA approved) | No controlled substance scheduling. |
Frequently asked questions
What is Baclofen?
Baclofen is a selective GABA-B receptor agonist and depressant used clinically for spasticity and investigated for alcohol use disorder. First synthesized in 1962 and FDA-approved in 1977, it is the only approved drug in its mechanistic class.
How long does Baclofen last?
Total duration by route of administration — Oral: 8 – 14 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Baclofen?
Psychedex publishes a dosage table for Baclofen on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Baclofen?
The highest-severity documented interactions for Baclofen: GHB, GBL (Lethal), Opioids (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Anticholinergics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Baclofen addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Baclofen: tolerance builds rapid; full reset takes 10.5 days; cross-tolerance develops with GHB, GBL, phenibut, other GABA-B active agents. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^Shaye H, Ishchenko A, Lam JH, et al. (2020) Structural basis of the activation of a metabotropic GABA receptor — Nature doi:10.1038/s41586-020-2408-4
- [3] ^abAmeisen O (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician — Alcohol and Alcoholism PMID:15596425
- [4]
- [5] ^abcdLiu J, Wang LN (2019) Baclofen for alcohol withdrawal — Cochrane Database of Systematic Reviews PMID:31689723
- [6] ^abcdIqbal M, Modi P, Sehgal K, et al. (2026) Clinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review — CNS Drugs PMID:41555041
references
- [1]
- [2] ^abcShaye H, Ishchenko A, Lam JH, et al. (2020) Structural basis of the activation of a metabotropic GABA receptor — Nature doi:10.1038/s41586-020-2408-4
- [3] ^abAmeisen O (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician — Alcohol and Alcoholism PMID:15596425
- [4]
- [5] ^abcdLiu J, Wang LN (2019) Baclofen for alcohol withdrawal — Cochrane Database of Systematic Reviews PMID:31689723
- [6] ^abcdIqbal M, Modi P, Sehgal K, et al. (2026) Clinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review — CNS Drugs PMID:41555041